Stroke, Transient Ischemic Attack (TIA)
Conditions
Keywords
ischemia, stroke, transient ischemic attack (TIA), microbiome, microbiota, gut
Brief summary
The aim of the study is to verify the hypothesis that the microbial colonisation of the gut is changed in patients after stroke and that the gut microbiome of severely affected stroke patients differs from that of patients with only a short disruption of blood circulation in the brain (transient ischemic attack, TIA). For this, the composition of gut microbiota in stool samples will be analyzed by 454 pyrosequencing. Further, the correlation of stroke-associated changes in the microbiome with immunological parameters will be analyzed.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* age: 18 and older * ischemic cerebral infarction within the last 40 hours, anterior circulation infarct (ACA, MCA) and/or posterior circulation infarct (PCA, BA) of any severity * patient consent or consent by a legal representative * NIHSS \> or =9 (stroke patients) * NIHSS \< 1 (for TIA patients)
Exclusion criteria
* intracranial hemorrhage * preexisting dysphagia * signs of infection upon admission (clinical/paraclinical) * existing antibiotic therapy upon admission or within the last 2 weeks before admission * mechanical ventilation upon admission * participation in an interventional therapy study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| composition of intestinal microbiome | change between day 1, day 4, day 7, day 14 after stroke | The composition of the intestinal metagenome / microbiome will be determined by analyzing the 16S rRNA by 454 Pyrosequencing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| test of correlation between most changed group of bacteria with changes in immunological parameters (HLA-DR) | days 1, 4, 7 after stroke | Analysis of correlation between changes in microbiome (most changed group of bacteria, e.g. lactobacilli) with changes in immunological parameters (e.g. HLA-DR, IL-6, IL-10, CD4-lymphocytes from blood samples). |
Countries
Germany